Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs

Blood

Volumn 87, Issue 9, 1996, Pages 3892-3898

  Liu, Changnian ^a   Lambert, John M ^b   Teicher, Beverly A ^b   Blättler, Walter A ^b   O'Connor, Rosemary ^b  

^a IMMUNOGEN INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IMMUNOTOXIN; RICIN ANTIBODY; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRAFT; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

EID: 0029923246     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.9.3892.bloodjournal8793892     Document Type: Article

References (48)

1. Armitage JO: Treatment of non-Hodgkin's lymphoma. N Engl J Med, 328:1023, 1993
2. Frei E III: Curative cancer chemotherapy. Cancer Res 45:6523, 1985
3. Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A, O'Connell M: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Eng J Med 327:1342, 1992
4. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JK, Coltman CA, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Eng J Med 328:1002, 1993
5. Teicher BA: Drug Resistance in Oncology. New York, NY, Dekker, 1993
6. Yang CPH, Greenberger LM, Horwitz SB: Reversal of multi-drug resistance in tumor cells, in: Chou TC, Rideout DC (eds): Synergism and Antagonism in Chemotherapy. San Diego, CA, Academic 1991, p 311
7. Moscow JA, Cowan KH: Multidrug resistance. J Natl Cancer Inst 80:14, 1988
8. Arceci RJ: Clinical significance of P-glycoprotein in multi-drug resistant malignancies. Blood 81:2215, 1993
9. Kartner N, Riordan JR, Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285, 1983
10. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM: Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863, 1992
11. Ghetie V, Vitetta E: Immunotoxins in the therapy of cancer: From bench to clinic. Pharmacol Ther 63:209, 1994
12. Lambert JM, McIntyre G, Gauthier MN, Zullo D, Rao V, Steeves RM, Goldmacher VS, Blättler WA: The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry 30:3234, 1991
13. Lambert JM, Goldmacher VS, Collinson AR, Nadler LM, Blättler WA: An immunotoxin prepared with blocked ricin: A natural plant toxin adapted for therapeutic use. Cancer Res 51:6236, 1991
14. Nadler LM, Anderson KC, Marti G, Bates MP, Park E, Daley JF, Schlossman SF: B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 131:244, 1983
15. Anderson KC, Slaughenhoupt B, Bates MP, Pinkus G, O'Hora C, Schlossman SF, Nadler LM: Expression of human B-cell associated antigens on leukemias and lymphomas: A model of human B-cell differentiation. Blood 63:1424, 1984
16. Shah SA, Halloran PM, Ferns CA, Levine BA, Bourret LA, Goldmacher VS, Blättler WA: Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res 53:1360, 1993
17. Liu C, O'Connor R, Derr SM, Shah SA, Blättler WA: Potentiation of chemotherapy by anti-B4-blocked ricin against a human B-cell lymphoma in vitro and in vivo. Blood 82.140a, 1993 (abstr)
18. Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blättler WA, Taylor JA, Nadler LM: Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion. Blood 79:576, 1992
19. Grossbard ML, Lambert JM, Goldmacher VS, Blattler WA, Nadler LM: Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin. Cancer Res 52:4200, 1992
20. Grossbard ML, Lambert JM, Goldmacher VS, Freedman AS, Kinsella J, Ducello DP, Rabinowe SN, Elisea L, Carol F, Taylor JA, Blättler WA, Epstein CL, Nadler LM: Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 11:726, 1993
21. O'Connor R, Liu C, Ferris CA, Teicher BA, Guild BC, Corvi C, Liu Y, Arceci RJ, Goldmacher VS, Lambert JM, Blättler WA: Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 86:4286, 1995
22. Chabner BA, Wilson W: Reversal of multidrug resistance. J Clin Oncol 9:4, 1991
23. Sparano JA, Wiernik PH, Leaf A, Dutcher JP: Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 11:1071, 1993
24. Chang AY. Introduction to ifosfamide/carboplatin/etoposide chemotherapy. Semin Oncol 22:1, 1995
25. Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, Perkins JB, Creger RJ, Ballester OF, Hiemenz JH, Janssen WE, Zorsky PE: Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: Toxicity profile. J Clin Oncol 13:323, 1995
26. Boros L, Garrow GC, Asbury RF, Chang AY: Phase I study of escalating doses of paclitaxel (Taxol) with fixed doses of ifosfamide, carboplatin, and etoposide. Semin Oncol 22:28, 1995
27. Teicher BA, Herman TS, Holden SA, Eder JP: Chemotherapeutic potentiation through interaction at the level of DNA, in Chou T-C, Rideout DC (eds). Synergism and Antagonism in Chemotherapy, Orlando, FL, Academic 1991, p 541
28. Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52:203, 1965
29. O'Connor R, Liu C, Teicher BA, Shah SA, Blättler WA: Anti-B4-blocked ricin as a candidate to reverse multidrug-resistance in B-cell tumors. Blood 82.140a, 1993 (abstr)
30. + human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD 19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 79:3116, 1992
31. Yokota S, Hara H, Luo Y, Seon BK: Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia Immunotoxins by recombinant α-interferon and daunorubicin. Cancer Res 50:32, 1990
32. Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES: Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood 84:702, 1994
33. Dietel M: Second international symposium on cytostatic drug resistance. Cancer Res 53:2683, 1993
34. Keisuke Y, Tsuruo T: Reversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 49:5002, 1989
35. Cornwell MM, Pastan I, Gottesman MM: Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein J Biol Chem 262:2166, 1987
36. Tsuruo T, Iida H, Tsukagoshi S, Sukurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967, 1981
37. Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S, Sukurai Y: Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and Adriamycin in drug-resistant tumor cells. Cancer Res 44:4303, 1984
38. Chauffert B, Rey D, Coudert B, Dumas M, Martin F: Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumor cells. Br J Cancer 56:119, 1987
39. Ganapathi R, Grabowski D: Enhancement of sensitivity Adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Res 43:3696, 1983
40. Zamora JM, Beck WT: Chloroquine enhancement of anticancer drug cytotoxicity in multidrug resistant human leukemic cells. Biochem Pharmacol 35:4303, 1986
41. Yang CH, DePinho SG, Greenberg LM, Arceci RJ, Horowitz SB: Progesterone interacts with P-glycoprotein in multidrug-resistant cells in the endometrium of gravid uterus. J Biol Chem 264:782, 1989
42. Slater LM, Sweet P, Stupecky M, Gupta S: Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 77:1045, 1986
43. List AF, Spier C, Greer J, Wolff S, Hufter J, Dorr R, Salmon, S, Futscher B, Baier M, Dalton W: Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652, 1993
44. r 170,000 glycoprotein (gp170) binding studies. Cancer Res 54:441, 1994
45. Rittmann-Grauer L, Yong MA, Sanders V, Mackensen DG: Reversal of vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft. Cancer Res 52:1810, 1992
46. FitzGerald DJ, Willingham MC, Cardarelli CO, Hamada H, Tsuruo T, Gottesman MM, Pastan I: A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci USA 84:4288, 1987
47. Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parrillo JE, Young RC: Verapamil and Adriamycin in the treatmen of drug-resistant ovarian cancer patients. J Clin Oncol 5:641, 1987
48. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, Salmon SE: Drug resistance in multiple myeloma and non-Hodgkins lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415, 1989